App-Quantinova.ai

Clinically significant changes of receptors status (ER, PR and HER2) after receiving neoadjuvant chemotherapy (NACT) in breast cancer (BC) predicts the prognosis and guides the choice of the optimal adjuvant therapy (AT): Retesting of the receptor status should be mandatory

Tarek M. a. Abdel-Fatah - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Predicting distant recurrence of ER+ HER2- breast cancer after 5 years of endocrine therapy: The CTS5-tool validation in real life

Josephine Van Cauwenberge - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

IL6ST, a biomarker of endocrine therapy response, has potential in identifying a subgroup of women with ER+ DCIS who are more likely to benefit from adjuvant endocrine therapy

Carlos Martinez-Perez - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Surgical management of DCIS during the UK Sloane audit project

Cliona Clare Kirwan - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

The evolving role of pre-pectoral acellular dermal matrix -assisted approach in implant-based immediate breast reconstruction following conservative mastectomy: A prospective observational study

Salim Tayeh - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Codeine

Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes

Chantal Merens - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Olaparib

Method development for a ‘Study within a Trial’ using a cluster stepped wedge trial design: Evaluating a patient decision aid video on patients’ decisional conflict in the PRIMETIME study

Indrani Subarna Bhattacharya - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Does the addition of a patient decision aid video reduce decisional conflict in patients considering a de-escalation of radiotherapy trial? Results from the PRIMETIME study

Indrani Subarna Bhattacharya - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Evaluation of genomic changes in ductal carcinoma in situ as potential biomarkers of recurrence risk

Dorothea Lesche - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

TP53

Development and validation of novel biomarkers of response to radiotherapy in breast cancer

James Meehan - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

In vitro chemo interrogation of viable circulating tumor associated cells from breast cancer patients

Timothy Crook - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Breast cancer

N/A

Physician practice settings and BRCA1/2 testing rates in HER2- advanced breast cancer (ABC): Results from the European component of a multi-country real-world study

Michael P. Lux - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

BRCA1/2 testing in adult women with HER2- advanced breast cancer (ABC): Results from a US real world study

Michael P. Lux - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Estrogen receptor beta repurposes EZH2 to inhibit oncogenic NFκB signaling in triple negative breast cancer

Kirsten GM Aspros - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

EZH2

The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer

Athina Giannoudis - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Breast cancer

Tamoxifen

Oral selective estrogen receptor degrader AZD9496 demonstrated preclinical model specific differences to fulvestrant in estrogen receptor degradation, agonism and anti-tumour effects

Mandy Lawson - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Endometrial Cancer

Fulvestrant

Functional characterization of ESR1 fusions in breast cancer

Xuxu Gou - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Alora

In-depth genomic analysis of acquired resistance to multiple sequential lines of endocrine therapy in breast cancer

Arran K Turnbull - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Anastrozole

A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer

John FR Robertson - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

Identification of mechanisms driving acquired chemoresistance in preclinical breast cancer models of taxane resistance

Karen J Taylor - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Paclitaxel

Filters

45280 Abstracts